{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T17:58:46Z","timestamp":1792173526455,"version":"4.4.0"},"reference-count":88,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,2,4]],"date-time":"2021-02-04T00:00:00Z","timestamp":1612396800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["EBioMedicine"],"published-print":{"date-parts":[[2021,3]]},"DOI":"10.1016\/j.ebiom.2021.103250","type":"journal-article","created":{"date-parts":[[2021,2,26]],"date-time":"2021-02-26T17:55:12Z","timestamp":1614362112000},"page":"103250","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"special_numbering":"C","title":["Development of a novel, fully human, anti-PCSK9 antibody with potent hypolipidemic activity by utilizing phage display-based strategy"],"prefix":"10.1016","volume":"65","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0087-5646","authenticated-orcid":false,"given":"Menglong","family":"Xu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaoxin","family":"Lei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manman","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ke","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenxiu","family":"Lv","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Panpan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tuo","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenchen","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Mei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhipan","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhengli","family":"Bai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huajing","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiwei","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4992-8876","authenticated-orcid":false,"given":"Shuhua","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.ebiom.2021.103250_bib0001","doi-asserted-by":"crossref","first-page":"e56","DOI":"10.1161\/CIR.0000000000000659","article-title":"Heart disease and stroke statistics-2019 update: a report from the American heart association","volume":"139","author":"Benjamin","year":"2019","journal-title":"Circulation."},{"issue":"2","key":"10.1016\/j.ebiom.2021.103250_bib0002","doi-asserted-by":"crossref","first-page":"e38","DOI":"10.1161\/ATV.0000000000000073","article-title":"Statin safety and associated adverse events: a scientific statement from the American heart association","volume":"39","author":"Newman","year":"2019","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"3","key":"10.1016\/j.ebiom.2021.103250_bib0003","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1073\/pnas.0335507100","article-title":"The secretory proprotein convertase neural apoptosis-regulated convertase 1 (NARC-1): liver regeneration and neuronal differentiation","volume":"100","author":"Seidah","year":"2003","journal-title":"Proc Natl Acad Sci United States Am"},{"issue":"6","key":"10.1016\/j.ebiom.2021.103250_bib0004","doi-asserted-by":"crossref","first-page":"1820","DOI":"10.1073\/pnas.0712064105","article-title":"Molecular basis for LDL receptor recognition by PCSK9","volume":"105","author":"Kwon","year":"2008","journal-title":"Proc Natl Acad Sci United States Am"},{"issue":"9","key":"10.1016\/j.ebiom.2021.103250_bib0005","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1194\/jlr.M028563","article-title":"Molecular characterization of proprotein convertase subtilisin\/kexin type 9-mediated degradation of the LDLR","volume":"53","author":"Wang","year":"2012","journal-title":"J Lipid Res"},{"issue":"12","key":"10.1016\/j.ebiom.2021.103250_bib0006","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1038\/embor.2011.205","article-title":"Mechanistic implications for LDL receptor degradation from the PCSK9\/LDLR structure at neutral pH","volume":"12","author":"Lo Surdo","year":"2011","journal-title":"EMBO Rep"},{"issue":"12","key":"10.1016\/j.ebiom.2021.103250_bib0007","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1016\/j.ebiom.2015.12.006","article-title":"PCSK9 inhibitors: what lies beyond monoclonal antibodies?","volume":"2","year":"2015","journal-title":"EBioMedicine"},{"issue":"10","key":"10.1016\/j.ebiom.2021.103250_bib0008","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1093\/ndt\/gfz108","article-title":"Protein convertase subtilisin\/kexin type 9 biology in nephrotic syndrome: implications for use as therapy","volume":"35","author":"Busuioc","year":"2020","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.ebiom.2021.103250_bib0009","doi-asserted-by":"crossref","first-page":"e251","DOI":"10.1016\/j.atherosclerosis.2018.06.800","article-title":"Serum PCSK9 levels are increased in obese subjects and negatively correlated with a mediterranean diet score","volume":"275","author":"Angouridis","year":"2018","journal-title":"Atherosclerosis"},{"issue":"11","key":"10.1016\/j.ebiom.2021.103250_bib0010","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1111\/dom.12536","article-title":"Effect of statin therapy on plasma proprotein convertase subtilisin kexin 9 (PCSK9) concentrations: a systematic review and meta-analysis of clinical trials","volume":"17","author":"Sahebkar","year":"2015","journal-title":"Diabetes Obes Metab"},{"issue":"1","key":"10.1016\/j.ebiom.2021.103250_bib0011","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12929-019-0592-z","article-title":"Development of therapeutic antibodies for the treatment of diseases","volume":"27","author":"Lu","year":"2020","journal-title":"J Biomed Sci"},{"issue":"12","key":"10.1016\/j.ebiom.2021.103250_bib0012","doi-asserted-by":"crossref","first-page":"2475","DOI":"10.1007\/s00216-019-01714-4","article-title":"The 2018 nobel prize in chemistry: phage display of peptides and antibodies","volume":"411","author":"Barderas","year":"2019","journal-title":"Anal Bioanal Chem"},{"issue":"2","key":"10.1016\/j.ebiom.2021.103250_bib0013","doi-asserted-by":"crossref","first-page":"276","DOI":"10.3109\/07388551.2014.958978","article-title":"Phage antibody display libraries: a powerful antibody discovery platform for immunotherapy","volume":"36","author":"Zhao","year":"2016","journal-title":"Crit Rev Biotechnol"},{"key":"10.1016\/j.ebiom.2021.103250_bib0014","series-title":"Therapeutic antibodies: methods and protocols","first-page":"293","article-title":"In Vitro antibody affinity maturation targeting germline hotspots","author":"Ho","year":"2009"},{"key":"10.1016\/j.ebiom.2021.103250_bib0015","doi-asserted-by":"crossref","unstructured":"Bain B, Brazil M. Adalimumab. Nat Rev Drug Discovery. 2003;2(9):693-4.","DOI":"10.1038\/nrd1182"},{"issue":"7","key":"10.1016\/j.ebiom.2021.103250_bib0016","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1080\/19420862.2016.1212149","article-title":"Phage display-derived human antibodies in clinical development and therapy","volume":"8","author":"Frenzel","year":"2016","journal-title":"mAbs"},{"issue":"1","key":"10.1016\/j.ebiom.2021.103250_bib0017","doi-asserted-by":"crossref","first-page":"73","DOI":"10.4161\/mabs.27240","article-title":"Drugs derived from phage display: from candidate identification to clinical practice","volume":"6","author":"Nixon","year":"2014","journal-title":"mAbs"},{"issue":"6","key":"10.1016\/j.ebiom.2021.103250_bib0018","doi-asserted-by":"crossref","first-page":"664","DOI":"10.4161\/mabs.21728","article-title":"Tailored amino acid diversity for the evolution of antibody affinity","volume":"4","author":"Gonzalez-Munoz","year":"2012","journal-title":"mAbs"},{"key":"10.1016\/j.ebiom.2021.103250_bib0019","doi-asserted-by":"crossref","first-page":"986","DOI":"10.3389\/fimmu.2017.00986","article-title":"Facile affinity maturation of antibody variable domains using natural diversity mutagenesis","volume":"8","author":"Tiller","year":"2017","journal-title":"Front Immunol"},{"issue":"4","key":"10.1016\/j.ebiom.2021.103250_bib0020","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/j.jmb.2011.10.008","article-title":"In vitro affinity maturation of an anti-PSA antibody for prostate cancer diagnostic assay","volume":"414","author":"Muller","year":"2011","journal-title":"J Mol Biol"},{"issue":"1","key":"10.1016\/j.ebiom.2021.103250_bib0021","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.molimm.2008.07.013","article-title":"In vitro affinity maturation of human GM-CSF antibodies by targeted CDR-diversification","volume":"46","author":"Steidl","year":"2008","journal-title":"Mole Immunol"},{"issue":"12","key":"10.1016\/j.ebiom.2021.103250_bib0022","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1016\/j.tibs.2019.07.001","article-title":"Conservation and variability of the AUG initiation codon context in eukaryotes","volume":"44","author":"Hern\u00e1ndez","year":"2019","journal-title":"Trends Biochem Sci"},{"key":"10.1016\/j.ebiom.2021.103250_bib0023","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.jbiotec.2018.06.307","article-title":"Optimization of a high-cell-density polyethylenimine transfection method for rapid protein production in CHO-EBNA1 cells","volume":"281","author":"Stuible","year":"2018","journal-title":"J Biotechnol"},{"issue":"10","key":"10.1016\/j.ebiom.2021.103250_bib0024","doi-asserted-by":"crossref","first-page":"2064","DOI":"10.3390\/ijms18102064","article-title":"A novel fully human agonistic single chain fragment variable antibody targeting death receptor 5 with potent antitumor activity in vitro and in vivo","volume":"18","author":"Lei","year":"2017","journal-title":"Int J Mole Sci"},{"issue":"10","key":"10.1016\/j.ebiom.2021.103250_bib0025","doi-asserted-by":"crossref","first-page":"4363","DOI":"10.1073\/pnas.88.10.4363","article-title":"Linkage of recognition and replication functions by assembling combinatorial antibody Fab libraries along phage surfaces","volume":"88","author":"Kang","year":"1991","journal-title":"Proc Natl Acad Sci United States Am"},{"issue":"12","key":"10.1016\/j.ebiom.2021.103250_bib0026","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1093\/protein\/13.12.819","article-title":"WAM: an improved algorithm for modelling antibodies on the WEB","volume":"13","author":"Whitelegg","year":"2000","journal-title":"Protein Eng"},{"key":"10.1016\/j.ebiom.2021.103250_bib0027","first-page":"51","article-title":"Antibody variable regions: toward a unified modeling method","volume":"248","author":"Whitelegg","year":"2004","journal-title":"Methods Mole Biol"},{"issue":"3","key":"10.1016\/j.ebiom.2021.103250_bib0028","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/j.jmb.2016.08.019","article-title":"abYsis: Integrated antibody sequence and structure-management, analysis, and prediction","volume":"429","author":"Swindells","year":"2017","journal-title":"J Mole Biol"},{"key":"10.1016\/j.ebiom.2021.103250_bib0029","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.jbiotec.2014.11.007","article-title":"Design and construction of small perturbation mutagenesis libraries for antibody affinity maturation using massive microchip-synthesized oligonucleotides","volume":"194","author":"Xu","year":"2015","journal-title":"J Biotechnol"},{"issue":"6","key":"10.1016\/j.ebiom.2021.103250_bib0030","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0129125","article-title":"Effective optimization of antibody affinity by phage display integrated with high-throughput DNA synthesis and sequencing technologies","volume":"10","author":"Hu","year":"2015","journal-title":"PLoS One"},{"issue":"14","key":"10.1016\/j.ebiom.2021.103250_bib0031","doi-asserted-by":"crossref","first-page":"e115","DOI":"10.1093\/nar\/gnh110","article-title":"An efficient one-step site-directed and site-saturation mutagenesis protocol","volume":"32","author":"Zheng","year":"2004","journal-title":"Nucleic Acids Res"},{"issue":"4","key":"10.1016\/j.ebiom.2021.103250_bib0032","doi-asserted-by":"crossref","first-page":"4836","DOI":"10.1096\/fj.201802251R","article-title":"Lunasin attenuates oxidant-induced endothelial injury and inhibits atherosclerotic plaque progression in ApoE(-\/-) mice by up-regulating heme oxygenase-1 via PI3K\/Akt\/Nrf2\/ARE pathway","volume":"33","author":"Gu","year":"2019","journal-title":"FASEB J"},{"issue":"25","key":"10.1016\/j.ebiom.2021.103250_bib0033","doi-asserted-by":"crossref","first-page":"17732","DOI":"10.1074\/jbc.M113.541094","article-title":"Annexin A2 reduces PCSK9 protein levels via a translational mechanism and interacts with the M1 and M2 domains of PCSK9","volume":"289","author":"Ly","year":"2014","journal-title":"J Biol Chem"},{"issue":"3","key":"10.1016\/j.ebiom.2021.103250_bib0034","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1002\/jobm.201700455","article-title":"Using overlap-extension PCR technique to fusing genes for constructing recombinant plasmids","volume":"58","author":"Lu","year":"2018","journal-title":"J Basic Microbiol"},{"issue":"10","key":"10.1016\/j.ebiom.2021.103250_bib0035","doi-asserted-by":"crossref","first-page":"5313","DOI":"10.4049\/jimmunol.164.10.5313","article-title":"The IgG Fc contains distinct Fc receptor (FcR) binding sites: the leukocyte receptors Fc gamma RI and Fc gamma RIIa bind to a region in the Fc distinct from that recognized by neonatal FcR and protein A","volume":"164","author":"Wines","year":"2000","journal-title":"J Immunol"},{"issue":"7158","key":"10.1016\/j.ebiom.2021.103250_bib0036","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/nature06106","article-title":"Fc receptor but not complement binding is important in antibody protection against HIV","volume":"449","author":"Hessell","year":"2007","journal-title":"Nature"},{"issue":"7","key":"10.1016\/j.ebiom.2021.103250_bib0037","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/j.tips.2009.04.007","article-title":"Recombinant antibody therapeutics: the impact of glycosylation on mechanisms of action","volume":"30","author":"Jefferis","year":"2009","journal-title":"Trends Pharmacol Sci"},{"issue":"5","key":"10.1016\/j.ebiom.2021.103250_bib0038","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.1074\/jbc.M116.748525","article-title":"Engineering an IgG scaffold lacking effector function with optimized developability","volume":"292","author":"Jacobsen","year":"2017","journal-title":"J Biol Chem"},{"issue":"7","key":"10.1016\/j.ebiom.2021.103250_bib0039","doi-asserted-by":"crossref","first-page":"2426","DOI":"10.1002\/jps.21180","article-title":"Heterogeneity of monoclonal antibodies","volume":"97","author":"Liu","year":"2008","journal-title":"J Pharm Sci"},{"issue":"6","key":"10.1016\/j.ebiom.2021.103250_bib0040","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1002\/bit.21855","article-title":"C-terminal lysine variants in fully human monoclonal antibodies: investigation of test methods and possible causes","volume":"100","author":"Dick","year":"2008","journal-title":"Biotechnol Bioeng"},{"key":"10.1016\/j.ebiom.2021.103250_bib0041","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.atherosclerosis.2020.02.004","article-title":"Hsa-miR-140-5p down-regulates LDL receptor and attenuates LDL-C uptake in human hepatocytes","volume":"297","author":"Xu","year":"2020","journal-title":"Atherosclerosis"},{"issue":"W1","key":"10.1016\/j.ebiom.2021.103250_bib0042","doi-asserted-by":"crossref","first-page":"W474","DOI":"10.1093\/nar\/gkw361","article-title":"SAbPred: a structure-based antibody prediction server","volume":"44","author":"Dunbar","year":"2016","journal-title":"Nucleic Acids Res"},{"issue":"5","key":"10.1016\/j.ebiom.2021.103250_bib0043","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1038\/s41596-020-0312-x","article-title":"The HDOCK server for integrated protein-protein docking","volume":"15","author":"Yan","year":"2020","journal-title":"Nat Protoc"},{"issue":"W1","key":"10.1016\/j.ebiom.2021.103250_bib0044","doi-asserted-by":"crossref","first-page":"W322","DOI":"10.1093\/nar\/gkz397","article-title":"HawkDock: a web server to predict and analyze the protein-protein complex based on computational docking and MM\/GBSA","volume":"47","author":"Weng","year":"2019","journal-title":"Nucleic Acids Res"},{"issue":"6","key":"10.1016\/j.ebiom.2021.103250_bib0045","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1006\/mthe.2001.0333","article-title":"Long-term and therapeutic-level hepatic gene expression of human factor IX after naked plasmid transfer in vivo","volume":"3","author":"Miao","year":"2001","journal-title":"Mol Ther"},{"issue":"12","key":"10.1016\/j.ebiom.2021.103250_bib0046","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1038\/sj.mt.6300314","article-title":"Hydrodynamic gene delivery: its principles and applications","volume":"15","author":"Suda","year":"2007","journal-title":"Mol Ther"},{"issue":"1","key":"10.1016\/j.ebiom.2021.103250_bib0047","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1097\/MOL.0000000000000051","article-title":"Hyperlipidemia and cardiovascular disease: inflammation, dyslipidemia, and atherosclerosis","volume":"25","author":"Tietge","year":"2014","journal-title":"Curr Opin Lipidol"},{"issue":"7181","key":"10.1016\/j.ebiom.2021.103250_bib0048","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1038\/nature06796","article-title":"Translating molecular discoveries into new therapies for atherosclerosis","volume":"451","author":"Rader","year":"2008","journal-title":"Nature"},{"issue":"25 Suppl 2","key":"10.1016\/j.ebiom.2021.103250_bib0049","first-page":"S1","article-title":"2013 ACC\/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American college of cardiology\/American heart association task force on practice guidelines","volume":"129","author":"Stone","year":"2014","journal-title":"Circulation"},{"issue":"6","key":"10.1016\/j.ebiom.2021.103250_bib0050","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/j.jacl.2013.10.001","article-title":"An international atherosclerosis society position paper: global recommendations for the management of dyslipidemia","volume":"7","author":"Grundy","year":"2013","journal-title":"J Clin Lipidol"},{"issue":"4746","key":"10.1016\/j.ebiom.2021.103250_bib0051","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1126\/science.3513311","article-title":"A receptor-mediated pathway for cholesterol homeostasis (nobel lecture)","volume":"232","author":"Brown","year":"1986","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.ebiom.2021.103250_bib0052","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1111\/j.1432-1033.1977.tb11637.x","article-title":"Inhibition of cholesterol synthesis in vitro and in vivo by ML-236A and ML-236B, competitive inhibitors of 3-Hydroxy-3-methylglutaryl-coenzyme a reductase","volume":"77","author":"Endo","year":"1977","journal-title":"Eur J Biochem"},{"issue":"9","key":"10.1016\/j.ebiom.2021.103250_bib0053","doi-asserted-by":"crossref","first-page":"4307","DOI":"10.1210\/jc.2002-012041","article-title":"Regulation of hepatic low-density lipoprotein receptor, 3-hydroxy-3-methylglutaryl coenzyme A reductase, and cholesterol 7alpha-hydroxylase mRNAs in human liver","volume":"87","author":"Rudling","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"10.1016\/j.ebiom.2021.103250_bib0054","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1194\/jlr.M003566","article-title":"Strong induction of PCSK9 gene expression through HNF1alpha and SREBP2: mechanism for the resistance to LDL-cholesterol lowering effect of statins in dyslipidemic hamsters","volume":"51","author":"Dong","year":"2010","journal-title":"J Lipid Res"},{"issue":"3","key":"10.1016\/j.ebiom.2021.103250_bib0055","doi-asserted-by":"crossref","first-page":"749","DOI":"10.3892\/ijmm.2017.2879","article-title":"Hepatic HNF1 transcription factors control the induction of PCSK9 mediated by rosuvastatin in normolipidemic hamsters","volume":"39","author":"Dong","year":"2017","journal-title":"Int J Mol Med"},{"issue":"16","key":"10.1016\/j.ebiom.2021.103250_bib0056","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1056\/NEJMoa1501031","article-title":"Efficacy and safety of alirocumab in reducing lipids and cardiovascular events","volume":"372","author":"Robinson","year":"2015","journal-title":"N Engl J Med"},{"issue":"18","key":"10.1016\/j.ebiom.2021.103250_bib0057","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","article-title":"Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease","volume":"376","author":"Sabatine","year":"2017","journal-title":"N Engl J Med"},{"issue":"16","key":"10.1016\/j.ebiom.2021.103250_bib0058","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1056\/NEJMoa1614062","article-title":"Lipid-reduction variability and antidrug-antibody formation with bococizumab","volume":"376","author":"Ridker","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ebiom.2021.103250_bib0059","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.atherosclerosis.2018.01.001","article-title":"PCSK9 inhibitors in clinical practice: Expectations and reality","volume":"270","author":"Reiner","year":"2018","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.ebiom.2021.103250_bib0060","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.atherosclerosis.2017.11.027","article-title":"PCSK9 inhibitors in clinical practice: delivering on the promise?","volume":"270","author":"Stoekenbroek","year":"2018","journal-title":"Atherosclerosis"},{"issue":"10","key":"10.1016\/j.ebiom.2021.103250_bib0061","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1016\/j.amjcard.2017.02.020","article-title":"Effects of RG7652, a monoclonal antibody against PCSK9, on LDL-C, LDL-C subfractions, and inflammatory biomarkers in patients at high risk of or with established coronary heart disease (from the phase 2 EQUATOR study)","volume":"119","author":"Baruch","year":"2017","journal-title":"Am J Cardiol"},{"issue":"17","key":"10.1016\/j.ebiom.2021.103250_bib0062","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1093\/eurheartj\/ehv707","article-title":"Safety and efficacy of LY3015014, a monoclonal antibody to proprotein convertase subtilisin\/kexin type 9 (PCSK9): a randomized, placebo-controlled Phase 2 study","volume":"37","author":"Kastelein","year":"2016","journal-title":"Eur Heart J"},{"issue":"4","key":"10.1016\/j.ebiom.2021.103250_bib0063","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1016\/j.bbrc.2015.05.129","article-title":"Selection and characterization of human PCSK9 antibody from phage displayed antibody library","volume":"463","author":"Cao","year":"2015","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.ebiom.2021.103250_bib0064","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.3389\/fimmu.2017.01860","article-title":"Engineering of Fc fragments with optimized physicochemical properties implying improvement of clinical potentials for fc-based therapeutics","volume":"8","author":"Yang","year":"2017","journal-title":"Front Immunol"},{"issue":"12","key":"10.1016\/j.ebiom.2021.103250_bib0065","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1038\/nbt.4305","article-title":"Biopharmaceutical benchmarks 2018","volume":"36","author":"Walsh","year":"2018","journal-title":"Nat Biotechnol"},{"issue":"3","key":"10.1016\/j.ebiom.2021.103250_bib0066","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1111\/j.1476-5381.2010.00936.x","article-title":"Long-lasting target binding and rebinding as mechanisms to prolong in vivo drug action","volume":"161","author":"Vauquelin","year":"2010","journal-title":"Br J Pharmacol"},{"issue":"4","key":"10.1016\/j.ebiom.2021.103250_bib0067","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1517\/17460441003677725","article-title":"The dynamics of drug-target interactions: drug-target residence time and its impact on efficacy and safety","volume":"5","author":"Copeland","year":"2010","journal-title":"Expert Opin Drug Discovery"},{"key":"10.1016\/j.ebiom.2021.103250_bib0068","first-page":"37457","article-title":"Antibody-antigen kinetics constrain intracellular humoral immunity","volume":"6","author":"Bottermann","year":"2016","journal-title":"Sci Reports."},{"issue":"43","key":"10.1016\/j.ebiom.2021.103250_bib0069","doi-asserted-by":"crossref","first-page":"13225","DOI":"10.1073\/pnas.1518361112","article-title":"Inhibition of ErbB3 by a monoclonal antibody that locks the extracellular domain in an inactive configuration","volume":"112","author":"Lee","year":"2015","journal-title":"PNAS"},{"issue":"18_suppl","key":"10.1016\/j.ebiom.2021.103250_bib0070","doi-asserted-by":"crossref","first-page":"13507","DOI":"10.1200\/jco.2007.25.18_suppl.13507","article-title":"Induction of tumor cell death by anti-GD2 monoclonal antibodies (MoAb): Requirement of antibody Fc and a long residence time (slow koff)","volume":"25","author":"XU","year":"2007","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.ebiom.2021.103250_bib0071","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.ab.2013.07.025","article-title":"Off-rate screening for selection of high-affinity anti-drug antibodies","volume":"441","author":"Ylera","year":"2013","journal-title":"Anal Biochem"},{"issue":"12","key":"10.1016\/j.ebiom.2021.103250_bib0072","doi-asserted-by":"crossref","first-page":"6800","DOI":"10.1021\/acs.analchem.7b01221","article-title":"Comparison of three antihapten VHH selection strategies for the development of highly sensitive immunoassays for microcystins","volume":"89","author":"Pirez-Schirmer","year":"2017","journal-title":"Anal Chem"},{"issue":"7","key":"10.1016\/j.ebiom.2021.103250_bib0073","doi-asserted-by":"crossref","first-page":"2843","DOI":"10.1021\/jm5003815","article-title":"Efficient hit and lead compound evaluation strategy based on off-rate screening by surface plasmon resonance","volume":"57","author":"Liu","year":"2014","journal-title":"J Med Chem"},{"issue":"3","key":"10.1016\/j.ebiom.2021.103250_bib0074","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1007\/s11095-015-1821-0","article-title":"Monoclonal antibodies follow distinct aggregation pathways during production-relevant acidic incubation and neutralization","volume":"33","author":"Skamris","year":"2016","journal-title":"Pharm Res"},{"issue":"5","key":"10.1016\/j.ebiom.2021.103250_bib0075","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1002\/bit.26547","article-title":"Isotype dependent on-column non-reversible aggregation of monoclonal antibodies","volume":"115","author":"Farys","year":"2018","journal-title":"Biotechnol Bioeng"},{"issue":"1","key":"10.1016\/j.ebiom.2021.103250_bib0076","doi-asserted-by":"crossref","first-page":"512","DOI":"10.4049\/jimmunol.0900847","article-title":"Human IgG2 antibodies against epidermal growth factor receptor effectively trigger antibody-dependent cellular cytotoxicity but, in contrast to IgG1, only by cells of myeloid lineage","volume":"184","author":"Schneider-Merck","year":"2010","journal-title":"J Immunol"},{"issue":"5","key":"10.1016\/j.ebiom.2021.103250_bib0077","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1159\/000355972","article-title":"Antibody-dependent cellular cytotoxicity in patients on chronic hemodialysis","volume":"38","author":"Koch","year":"2013","journal-title":"Am J Nephrol"},{"issue":"5844","key":"10.1016\/j.ebiom.2021.103250_bib0078","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1126\/science.1144603","article-title":"Anti-inflammatory activity of human IgG4 antibodies by dynamic Fab arm exchange","volume":"317","author":"van der Neut Kolfschoten","year":"2007","journal-title":"Science"},{"issue":"23","key":"10.1016\/j.ebiom.2021.103250_bib0079","doi-asserted-by":"crossref","first-page":"16206","DOI":"10.1074\/jbc.M709988200","article-title":"Structural and functional characterization of disulfide isoforms of the human IgG2 subclass","volume":"283","author":"Dillon","year":"2008","journal-title":"J Biol Chem"},{"issue":"6","key":"10.1016\/j.ebiom.2021.103250_bib0080","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/j.copbio.2009.10.011","article-title":"Optimization of Fc-mediated effector functions of monoclonal antibodies","volume":"20","author":"Strohl","year":"2009","journal-title":"Curr Opin Biotechnol"},{"issue":"52","key":"10.1016\/j.ebiom.2021.103250_bib0081","doi-asserted-by":"crossref","first-page":"43492","DOI":"10.1074\/jbc.M112.394023","article-title":"The M2 module of the Cys-His-rich domain (CHRD) of PCSK9 protein is needed for the extracellular low-density lipoprotein receptor (LDLR) degradation pathway","volume":"287","author":"Saavedra","year":"2012","journal-title":"J Biol Chem"},{"issue":"24","key":"10.1016\/j.ebiom.2021.103250_bib0082","doi-asserted-by":"crossref","first-page":"9820","DOI":"10.1073\/pnas.0903849106","article-title":"A proprotein convertase subtilisin\/kexin type 9 neutralizing antibody reduces serum cholesterol in mice and nonhuman primates","volume":"106","author":"Chan","year":"2009","journal-title":"PNAS"},{"issue":"3","key":"10.1016\/j.ebiom.2021.103250_bib0083","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1086\/500615","article-title":"A spectrum of PCSK9 alleles contributes to plasma levels of low-density lipoprotein cholesterol","volume":"78","author":"Kotowski","year":"2006","journal-title":"Am J Hum Genet"},{"issue":"2","key":"10.1016\/j.ebiom.2021.103250_bib0084","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/j.atherosclerosis.2006.08.039","article-title":"The C679X mutation in PCSK9 is present and lowers blood cholesterol in a Southern African population","volume":"193","author":"Hooper","year":"2007","journal-title":"Atherosclerosis"},{"issue":"1","key":"10.1016\/j.ebiom.2021.103250_bib0085","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1194\/jlr.M900273-JLR200","article-title":"A new method for measurement of total plasma PCSK9: clinical applications","volume":"51","author":"Dubuc","year":"2010","journal-title":"J Lipid Res"},{"issue":"4","key":"10.1016\/j.ebiom.2021.103250_bib0086","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/j.jmb.2013.11.011","article-title":"An antibody against the C-terminal domain of PCSK9 lowers LDL cholesterol levels in vivo","volume":"426","author":"Schiele","year":"2014","journal-title":"J Mol Biol"},{"issue":"17","key":"10.1016\/j.ebiom.2021.103250_bib0087","doi-asserted-by":"crossref","first-page":"12882","DOI":"10.1074\/jbc.M110.113035","article-title":"A proprotein convertase subtilisin-like\/kexin type 9 (PCSK9) C-terminal domain antibody antigen-binding fragment inhibits PCSK9 internalization and restores low density lipoprotein uptake","volume":"285","author":"Ni","year":"2010","journal-title":"J Biol Chem"},{"issue":"46","key":"10.1016\/j.ebiom.2021.103250_bib0088","doi-asserted-by":"crossref","first-page":"31791","DOI":"10.1074\/jbc.M805971200","article-title":"Annexin A2 is a C-terminal PCSK9-binding protein that regulates endogenous low density lipoprotein receptor levels","volume":"283","author":"Mayer","year":"2008","journal-title":"J Biol Chem"}],"container-title":["EBioMedicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352396421000438?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352396421000438?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T19:03:52Z","timestamp":1762455832000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2352396421000438"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3]]},"references-count":88,"alternative-id":["S2352396421000438"],"URL":"https:\/\/doi.org\/10.1016\/j.ebiom.2021.103250","relation":{},"ISSN":["2352-3964"],"issn-type":[{"value":"2352-3964","type":"print"}],"subject":[],"published":{"date-parts":[[2021,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Development of a novel, fully human, anti-PCSK9 antibody with potent hypolipidemic activity by utilizing phage display-based strategy","name":"articletitle","label":"Article Title"},{"value":"EBioMedicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ebiom.2021.103250","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"103250"}}